🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

2,562 results for “Cancer” Clear

  1. Lutathera 370 MBq/mL solution for infusion, ATEZOLIZUMAB, Tevimbra 100 mg concentrate for solution for infusion, CARBOPLATIN, LysaKare 25 g/25 g solution for infusion, NETSPOT, ETOPOSIDE

    Novartis Pharmaceuticals

    Extensive stage small cell lung cancer (ES-SCLC)

    phase 2 small molecule active

    1 trial

  2. Lutetium (177Lu) rhPSMA-10.1 injection

    Blue Earth Diagnostics Ireland Ltd

    Metastatic castration-resistant prostate cancer (mCRPC)

    phase 2 small molecule active

    1 trial

  3. Luveltamab tazevibulin

    SUTRO BIOPHARMA, INC.

    Lung Cancer

    phase 2 small molecule terminated

    1 trial

  4. Luxdegalutamide, DZR123, -, -, DOCETAXEL, CABAZITAXEL, ABIRATERONE, DZR123, ENZALUTAMIDE

    Novartis Pharmaceuticals

    Metastatic castrate resistant prostate cancer (mCRPC)

    phase 2 small molecule active

    1 trial

  5. Luxdegalutamide, GOZETOTIDE, Pluvicto 1 000 MBq/mL solution for injection/infusion

    Novartis Pharmaceuticals

    Metastatic castration resistant prostate cancer (mCRPC)

    phase 2 small molecule active

    1 trial

  6. Lynparza 100 mg film-coated tablets, CYCLOPHOSPHAMIDE, Lynparza 150 mg film-coated tablets, DOCETAXEL, DOXORUBICIN, CARBOPLATIN, EPIRUBICIN

    Shanghai Reinovax Biologics Co.,LTD

    Early invasive triple negative breast cancer with positive HRD status (acc. to Myriad mychoice© test)

    phase 2 small molecule active

    1 trial

  7. Lynparza 100 mg film-coated tablets, IMFINZI 50 mg/mL concentrate for solution for infusion., Faslodex 250 mg solution for injection., Lynparza 150 mg film-coated tablets, Zoladex 3.6 mg Implant

    Ningbo Cancer Hospital

    ER-positive and HER2-negative metastatic or locally advanced breast cancer with either a germline or somatic BRCA mutation, or a deleterious alteration of other genes involved in homologous recombination repair (HRR) or in MSI status.

    phase 2 small molecule active

    1 trial

  8. Lynparza 100 mg film-coated tablets, Lynparza 150 mg film-coated tablets

    Fondazione Telethon ETS

    BRCA wild-type advanced ovarian, fallopian tube and primitive peritoneal cancer

    phase 2 small molecule active

    1 trial

  9. Lynparza 150 mg film-coated tablets, IMFINZI 50 mg/mL concentrate for solution for infusion.

    AstraZeneca AB

    Stage IV Non Small Cell Lung Cancer whose tumors lack EGFR mutations and ALK fusions

    phase 2 small molecule active

    1 trial

  10. Lynparza 150 mg film-coated tablets, Lynparza 100 mg film-coated tablets

    Fondazione Telethon ETS

    recurrent ovarian cancer wild type for germline and somatic BRCA 1 and 2 genes

    phase 2 small molecule active

    1 trial

  11. Lytgobi 4 mg film-coated tablets, 5-FU medac 50 mg/ml, Injektionslösung, Oxaliplatin Kabi 5 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Tevimbra 100 mg concentrate for solution for infusion, Leucovorin 10 mg/ml Lösung zur Injektion/ Infusion

    The George Institute

    Colorectal cancer

    phase 2 small molecule active

    1 trial

  12. M1774, M1774, M1774, M1774, M4076, Zejula 100 mg film-coated tablets

    Merck Sharp and Dohme

    Epithelial ovarian cancer that progressed on prior PARP inhibitor therapy

    phase 2 small molecule active

    1 trial

  13. M9140

    Merck Sharp and Dohme

    Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  14. M9140

    Merck Sharp and Dohme

    Gastric Cancer

    phase 2 small molecule active

    1 trial

  15. METFORAL 850 mg compresse rivestite con film

    Fondazione Telethon ETS

    Triple negative breast cancer

    phase 2 small molecule active

    1 trial

  16. MIDAZOLAM , ODM-208 100 mg Tablet, ODM-208 50 mg Tablet, ODM-208 25 mg Tablet, ODM-208 5 mg film-coated tablet

    Orion Laboratories Pty.

    Metastatic castration-resistant prostate cancer.

    phase 2 small molecule active

    1 trial

  17. MIE

    The First People's Hospital of Lianyungang

    Esophageal Cancer

    phase 2 other active

    1 trial

  18. MK-1022, -, MK-1084, MK-1084, MK-2870, MK-1084, CETUXIMAB , MK-1084

    Merck Sharp and Dohme

    Non-small Cell Lung Cancer (NSCLC)

    phase 2 small molecule active

    1 trial

  19. MK-3120

    Merck Sharp and Dohme

    High-risk non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors

    phase 2 small molecule active

    1 trial

  20. MKC-1

    CASI Pharmaceuticals

    Pancreatic Cancer

    phase 2 small molecule completed

    1 trial

  21. MKC-1

    CASI Pharmaceuticals

    Advanced Cancer

    phase 2 small molecule completed

    2 trials

  22. MKC-1

    CASI Pharmaceuticals

    Breast Cancer

    phase 2 small molecule completed

    1 trial

  23. MKC-1

    CASI Pharmaceuticals

    Ovarian Cancer

    phase 2 small molecule completed

    1 trial

  24. MOGAMULIZUMAB

    Ningbo Cancer Hospital

    Cutaneous T-cell lymphoma, a category of cancers of lymphocytes (a type of white blood cells) that primarily involve the skin, Cutaneous T-cell lymphoma (Mycosis Fungoides (MF)) and Sézary Syndrome (SS))

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources